Inhibitors of SGLT and uses thereof
AssigneesThe Regents of the University of Michigan, Wayne State University
InventorsYuqing Chen, Jifeng Zhang, Jie Xu, Xiubin Liang, Jian-Ping Jin, Fei Sun
Life of this patent
Estimating the term…
Abstract
This invention is in the field of medicinal pharmacology. In particular, the present invention relates to pharmaceutical agents which function as inhibitors of sodium-glucose cotransporter (SGLT) activity. The invention further relates to methods of treating and/or ameliorating symptoms related to cystic fibrosis (CF), comprising administering to a subject (e.g., a human patient) a composition comprising one or more pharmaceutical agents which function as inhibitors of SGLT activity.
Claims1
A method for treating cystic fibrosis (CF), and/or symptoms related to any form and/or mutation of CF in a human subject, comprising administering to the human subject a composition comprising a pharmaceutical agent capable of inhibiting SGLT1 activity,
- wherein the pharmaceutical agent is sotagliflozin (LX4211),
- wherein administration results in an increase in serum albumin level or an increase in total serum protein level of the subject,
- wherein the one or more symptoms related to CF include one or more selected from hypokalemia, hyperglycemia, dyslipidemia, hypoalbuminemia, and hypoproteinemia.
Dependencies are inferred from the claim text.